115 related articles for article (PubMed ID: 38159843)
1. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy.
Shen W; Lyu Q; Yi R; Sun Y; Zhang W; Wei T; Zhang Y; Shi J; Zhang J
J Adv Res; 2023 Dec; ():. PubMed ID: 38159843
[TBL] [Abstract][Full Text] [Related]
2. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
[No Abstract] [Full Text] [Related]
3. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy.
Sun Y; Shen W; Hu S; Lyu Q; Wang Q; Wei T; Zhu W; Zhang J
J Exp Clin Cancer Res; 2023 Mar; 42(1):65. PubMed ID: 36932427
[TBL] [Abstract][Full Text] [Related]
4. Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway.
Li M; Shan W; Hua Y; Chao F; Cui Y; Lv L; Dou X; Bian X; Zou J; Li H; Lin W
Front Cell Dev Biol; 2021; 9():661602. PubMed ID: 34136482
[TBL] [Abstract][Full Text] [Related]
5. Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma.
Singh MP; Cho HJ; Kim JT; Baek KE; Lee HG; Kang SC
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31311167
[TBL] [Abstract][Full Text] [Related]
6. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
7. SIRT6-PARP1 is involved in HMGB1 polyADP-ribosylation and acetylation and promotes chemotherapy-induced autophagy in leukemia.
Kong Q; Li Y; Liang Q; Xie J; Li X; Fang J
Cancer Biol Ther; 2020 Apr; 21(4):320-331. PubMed ID: 31928132
[TBL] [Abstract][Full Text] [Related]
8. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy.
Yang M; Liu L; Xie M; Sun X; Yu Y; Kang R; Yang L; Zhu S; Cao L; Tang D
Autophagy; 2015; 11(2):214-24. PubMed ID: 25607248
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
10. The
Bian X; Wang X; Zhang Q; Ma L; Cao G; Xu A; Han J; Huang J; Lin W
Front Oncol; 2020; 10():565820. PubMed ID: 33134168
[TBL] [Abstract][Full Text] [Related]
11. Extracellular Vesicles Derived circSH3PXD2A Inhibits Chemoresistance of Small Cell Lung Cancer by miR-375-3p/YAP1.
Chao F; Zhang Y; Lv L; Wei Y; Dou X; Chang N; Yi Q; Li M
Int J Nanomedicine; 2023; 18():2989-3006. PubMed ID: 37304971
[TBL] [Abstract][Full Text] [Related]
12. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
[TBL] [Abstract][Full Text] [Related]
13. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase 1-sirtuin 1 functional interplay regulates LPS-mediated high mobility group box 1 secretion.
Walko TD; Di Caro V; Piganelli J; Billiar TR; Clark RS; Aneja RK
Mol Med; 2015 Mar; 20(1):612-24. PubMed ID: 25517228
[TBL] [Abstract][Full Text] [Related]
15. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
16. High mobility group box-1 release from H
Ye TJ; Lu YL; Yan XF; Hu XD; Wang XL
World J Gastroenterol; 2019 Sep; 25(36):5434-5450. PubMed ID: 31576091
[TBL] [Abstract][Full Text] [Related]
17. MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.
Tong Q; Ouyang S; Chen R; Huang J; Guo L
Am J Cancer Res; 2019; 9(9):1938-1956. PubMed ID: 31598396
[TBL] [Abstract][Full Text] [Related]
18. MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma.
Manzoor S; Saber-Ayad M; Maghazachi AA; Hamid Q; Muhammad JS
Neoplasia; 2022 Feb; 24(2):76-85. PubMed ID: 34952246
[TBL] [Abstract][Full Text] [Related]
19. PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.
Li Q; Li ZM; Sun SY; Wang LP; Wang PX; Guo Z; Yang HW; Ye JT; Lu J; Liu PQ
Acta Pharmacol Sin; 2019 May; 40(5):589-598. PubMed ID: 30030529
[TBL] [Abstract][Full Text] [Related]
20. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
